Logo
x

Search

Subscribe Now

 Trodelvy

Marengo Therapeutics Partners with Gilead to Conduct Clinical Trial of Invikafusp alfa Plus Trodelvy for Metastatic TNBC and Breast Cancers

Marengo Therapeutics Partners with Gilead to Conduct Clinical Trial of Invikafusp alfa Plus Trodelvy for Metastatic TNBC and Breas...

  • September 13, 2024
Insights+: EMA Marketing Authorization of New Drugs in July 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

  • August 25, 2023
Gilead’s Trodelvy (sacituzumab govitecan) Receives EC’s Approval for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead’s Trodelvy (sacituzumab govitecan) Receives EC’s Approval for Pre-Treated HR+/HER2- Metastatic Breast Cancer

  • July 28, 2023
Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer

  • June 23, 2023
Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breas...

  • June 6, 2023
Gilead Reports EMA's Validation of MAA for Trodelvy (sacituzumab govitecan-hziy) to Treat HR+/HER2- Metastatic Breast Cancer

Gilead Reports EMA's Validation of MAA for Trodelvy (sacituzumab govitecan-hziy) to Treat HR+/HER2- Metastatic Breast Cancer

  • January 3, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.